In this article, we will be taking a look at the Top 5 Best-Selling Cancer Drugs. If you wish to learn about the cancer treatment market, head straight to the Top 15 Best-Selling Cancer Drugs.
5. Darzalex
Total Sales: 13.9 billion
Darzalex (daratumumab) is a monoclonal antibody for multiple myeloma, demonstrating substantial commercial success. In 2023, its net sales reached USD 5,277 million in the U.S. and USD 4,467 million globally, reflecting a robust growth trajectory. Genmab’s financial performance saw net sales of USD 7,194 million in the first nine months of 2023, a notable increase from the same period in 2022. With a 38.7% growth worldwide, Darzalex is a pharmaceutical standout, actively contributing to treating multiple myeloma.
4. Imbruvica
Total Sales: 15.2 billion
Imbruvica (ibrutinib), a BTK inhibitor, is a top best-selling cancer drug for chronic lymphocytic leukemia, small lymphocytic lymphoma, and Waldenstrom’s macroglobulinemia. Approved by the FDA in 2013, it blocks Bruton’s tyrosine kinase, inhibiting cancer cell growth. Imbruvica is a commercial success, generating around $7.2 billion in global sales in 2022, reflecting its effectiveness and widespread clinical use.
3. Opdivo
Total Sales: 17.8 billion
Opdivo (nivolumab), widely used in cancer treatment, is often combined with Yervoy (ipilimumab). It demonstrates long-term efficacy in advanced renal cell carcinoma and adjuvant therapy of resected melanoma and esophageal/GEJ cancer. Opdivo’s cost, especially in combination therapy, raises considerations, prompting studies on its cost-effectiveness.
2. Revlimid
Total Sales: 22.8 billion
Revlimid (lenalidomide), standing second among the top best-selling cancer drugs, is an immunomodulatory drug widely used for treating multiple myeloma, bone marrow disorders, and myelodysplastic syndrome. FDA-approved in combination with dexamethasone for newly diagnosed multiple myeloma, it has shown effectiveness. However, clinical trials indicate an increased risk of developing certain cancers like acute myelogenous leukemia. Financially, Revlimid has been a top-selling cancer drug, generating over $20 billion in annual sales.
1. Keytruda
Total Sales: 38.1 billion
Keytruda (pembrolizumab) is a leading cancer immunotherapy drug, generating substantial revenue with over $6.3 billion in sales during Q3 2023, a 17% increase from the previous year. The drug has maintained strong growth, priced at $11,115.04 per dose every three weeks and $22,230.08 every six weeks. Keytruda’s versatility extends to various disease stages, including metastatic and earlier-stage indications like triple-negative breast cancer, along with approval for adjuvant treatment in non-small cell lung cancer and is also called the best selling drug in the world.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also take a peek at the 30 Best Cardiology Hospitals In the US and the 20 Countries With The Highest Life Expectancy in the World.
